1,2-二氟-3-(甲硫基)苯 | 130922-38-2

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: 1,2-二氟-3-(甲硫基)苯
• 英文名称: 2,3-Difluorothioanisole
• 英文别名: 1,2-difluoro-3-methylsulfanylbenzene
• CAS: 130922-38-2
• 化学式: C₇H₆F₂S
• 分子量: 160.19
• InChiKey: NNHPBLZNIVMRPQ-UHFFFAOYSA-N

物化性质

• 沸点：
  165.4±30.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] STAT INHIBITORY COMPOUNDS AND COMPOSITIONS<br/>[FR] COMPOSÉS ET COMPOSITIONS INHIBITEURS DE STAT
  申请人：JANPIX LTD

  公开号：WO2021178907A1

  公开（公告）日：2021-09-10

  Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for the inhibition of Signal Transducer and Activator of Transcription 5a and 5b (STAT5). Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as, for example, breast cancer and pancreatic cancer.

  提供的是化合物和包含这些化合物的药物组合物，它们对于抑制信号转导子和转录激活子5a和5b（STAT5）有益。此外，这些主题化合物和组合物对于治疗癌症，例如乳腺癌和胰腺癌，是有用的。
• [EN] NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES UTILES EN TANT QU'INHIBITEURS SÉLECTIFS D'AURORA A
  申请人：JACOBIO PHARMACEUTICALS CO LTD

  公开号：WO2021147974A1

  公开（公告）日：2021-07-29

  Provided are compounds of formula (I), or pharmaceutically acceptable salts thereof, which can be used for inhibiting the activity of Aurora A and treating cancer mediated by Aurora A.

  提供的是式（I）的化合物，或其药学上可接受的盐，可用于抑制Aurora A的活性并治疗由Aurora A介导的癌症。
• Therapeutic heterocyclic compounds
  申请人：Gilead Sciences, Inc.

  公开号：US11040033B2

  公开（公告）日：2021-06-22

  Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed:

  本发明公开了具有以下式 I 和/或式 II 的化合物及其使用和制备方法：
• Substituted amino acids as integrin inhibitors
  申请人：Pliant Therapeutics, Inc.

  公开号：US11180494B2

  公开（公告）日：2021-11-23

  The invention relates to compounds of formula (I): or a salt thereof, wherein R1, G, L1, L2, L3, and Y are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are inhibitors of one, or both of, αvβ1 integrin and αvβ6 integrin that are useful for treating fibrosis such as in nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

  本发明涉及式 (I) 化合物： 或其盐，其中 R1、G、L1、L2、L3 和 Y 如本文所述。式（I）化合物及其药物组合物是αvβ1整合素和αvβ6整合素中一种或两种的抑制剂，可用于治疗纤维化，如非酒精性脂肪性肝炎（NASH）、特发性肺纤维化（IPF）和非特异性间质性肺炎（NSIP）。
• MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF
  申请人：Crinetics Pharmaceuticals, Inc.

  公开号：US20200216415A1

  公开（公告）日：2020-07-09

  Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.